Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: first clinical experience
出版年份 2021 全文链接
标题
Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: first clinical experience
作者
关键词
Lung cancer, Neoadjuvant immunotherapy, Anti-PD-1, Thoracic surgery, Pembrolizumab
出版物
LUNG CANCER
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2021-01-22
DOI
10.1016/j.lungcan.2021.01.018
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Immunotherapy-related adverse effects on 18F-FDG PET/CT imaging
- (2020) Nemi Gandy et al. BRITISH JOURNAL OF RADIOLOGY
- The efficiency of 18F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer
- (2020) Xiuli Tao et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY
- (2020) William D. Travis et al. Journal of Thoracic Oncology
- Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
- (2020) Shugeng Gao et al. Journal of Thoracic Oncology
- Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis
- (2020) Xiaoxiang Zhou et al. BMC Medicine
- Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer
- (2020) Kosuke Hashimoto et al. Journal of Clinical Medicine
- Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC
- (2020) Pengfei Cui et al. Scientific Reports
- Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial
- (2019) Florian Eichhorn et al. BMC CANCER
- Impact of Specimen Characteristics on PD-L1 Testing in Non-Small Cell Lung Cancer: Validation of the IASLC PD-L1 Testing Guidelines
- (2019) Andréanne Gagné et al. Journal of Thoracic Oncology
- Immune Checkpoint Inhibition in Non-metastatic Non-small Cell Lung Cancer: Chance for Cure?
- (2019) David F. Heigener et al. DRUGS
- Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
- (2019) Jhanelle E. Gray et al. Journal of Thoracic Oncology
- P2.04-90 Nodal Immune Flare (NIF) Following Neoadjuvant Anti-PD-1 and Anti-CTLA-4 Therapy in Non-Small Cell Lung Cancer
- (2019) B. Sepesi et al. Journal of Thoracic Oncology
- Radiologic Pseudoprogression during Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer
- (2018) Sharyn I. Katz et al. Journal of Thoracic Oncology
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PET–CT
- (2018) Antonia Dimitrakopoulou-Strauss CANCER IMMUNOLOGY IMMUNOTHERAPY
- Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)
- (2018) Sabine Schmid et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- FDG PET/CT for assessing tumour response to immunotherapy
- (2018) Nicolas Aide et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Initial results of pulmonary resection following neoadjuvant nivolumab in patients with resectable non-small cell lung cancer
- (2018) Matthew J. Bott et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- Metabolic activity by 18F–FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC
- (2017) Kyoichi Kaira et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Indirect comparison between pembrolizumab and nivolumab for the treatment of non-small cell lung cancer: A meta-analysis of randomized clinical trials
- (2017) Tzu-Rong Peng et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms
- (2017) Danae A Delivanis et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients
- (2016) Mizuki Nishino et al. Journal for ImmunoTherapy of Cancer
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
- (2015) J. Naidoo et al. ANNALS OF ONCOLOGY
- Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies
- (2015) M. Ilie et al. ANNALS OF ONCOLOGY
- The 2015 World Health Organization Classification of Lung Tumors
- (2015) William D. Travis et al. Journal of Thoracic Oncology
- The International Association for the Study of Lung Cancer Lung Cancer Staging Project
- (2015) Hisao Asamura et al. Journal of Thoracic Oncology
- Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint
- (2014) Matthew D Hellmann et al. LANCET ONCOLOGY
- Non-small-cell lung cancer
- (2011) Peter Goldstraw et al. LANCET
- New Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines for Advanced Non–Small Cell Lung Cancer: Comparison With Original RECIST and Impact on Assessment of Tumor Response to Targeted Therapy
- (2010) Mizuki Nishino et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Surgery With or Without Preoperative Paclitaxel and Carboplatin in Early-Stage Non–Small-Cell Lung Cancer: Southwest Oncology Group Trial S9900, an Intergroup, Randomized, Phase III Trial
- (2010) Katherine M.W. Pisters et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-Term Results of the International Adjuvant Lung Cancer Trial Evaluating Adjuvant Cisplatin-Based Chemotherapy in Resected Lung Cancer
- (2009) Rodrigo Arriagada et al. JOURNAL OF CLINICAL ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started